Want to see ABBV full AI Analyst Report?
Earnings Data
Report Date
Jul 31, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
3.76Last Year’s EPS
2.97Same Quarter Last Year
Strong Buy
Based on 21 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and financial performance with multiple product growth drivers (Skyrizi, Rinvoq, neuroscience portfolio) and a raised full-year outlook. Substantial pipeline progress (regulatory submissions, combination Crohn's data, obesity signal) and major manufacturing investments reinforce long-term growth positioning. Offsets include expected HUMIRA biosimilar erosion, pressure in some oncology and aesthetic segments, selected clinical setbacks/non-differentiation and near-term acquired IPR&D expense impacts. On balance, highlights — including robust sales beats, double-digit growth for key franchises, guidance raise, and encouraging pipeline readouts — outweigh the lowlights.Company Guidance
Quarterly Financial Beat and Guidance Raise
Adjusted EPS of $2.65, $0.07 above guidance midpoint; total net revenues of $15.0 billion, beating expectations by ~$300 million and representing 12.4% sales growth. Company raised full-year adjusted EPS guidance by $0.12 to $14.08–$14.28 and increased full-year revenue outlook to approximately $67.3 billion (+$300 million).
Strong Immunology Performance (Skyrizi & Rinvoq)
Immunology revenues $7.3 billion, +$1.0 billion year-over-year. Skyrizi sales $4.5 billion, up 29.2% (operational). Rinvoq sales $2.1 billion, up 20.2% (operational). Skyrizi showing share gains across psoriasis, psoriatic arthritis and IBD; Skyrizi on track for >30% global sales growth in IBD this year.
Neuroscience Momentum
Neuroscience revenues nearly $2.9 billion, up 24.3% (operational). Vraylar $905 million, +18.4%; VYALEV $201 million, ~+10% sequential. Company preparing for potential U.S. approval and launch of tavapadon in Parkinson's later this year.
Selected Product Strengths and Category Leadership
Botox Therapeutic and other migraine portfolio delivering robust double-digit growth; Botox Cosmetic $668 million (+17%); Skyrizi demonstrated long-term radiographic data in psoriatic arthritis (nearly 90% no radiographic progression at 5 years) and new label additions for hard-to-treat psoriasis areas.
Pipeline Progress — Regulatory Submissions & Positive Readouts
U.S. submission of Rinvoq for alopecia areata; U.S. submission for Skyrizi subcutaneous induction in Crohn's with approval decision expected later this year; interim combination data (Skyrizi + ABBV-382) showing potential transformational efficacy in Crohn's.
Promising Early Obesity Data (ABBV-295)
Multiple-ascending-dose study of long-acting amylin analog ABBV-295 showed nearly 10% weight loss in 12 weeks in a predominantly male, nonobese cohort with favorable tolerability; half-life ~270 hours and potential for every-other-week or monthly dosing in future development.
Oncology Pipeline Actions & External BD
Expanded oncology assets via Remagen agreement for a PD-1/VEGF bispecific; Temab-A strategy shift to combination (Temab-A + bevacizumab) in all-comers colorectal cancer with reported ORR ~30% and disease control rate ~97% in early data; multiple ASCO readouts and acceleration discussions planned.
Capital Investment & Manufacturing Commitment
Announced part of $100 billion U.S. R&D and capital investment commitment: $1.4 billion pharmaceutical campus in North Carolina and $380 million for two plants in North Chicago to expand manufacturing capacity.
Strong Profitability and Margin Targets
Reported adjusted gross margin 83.6% of sales; adjusted operating margin 40.8% in Q1 (includes acquired IPR&D impact). Full-year targets include adjusted gross margin above 84% and an adjusted operating margin ratio of ~47.5%.
Financial Flexibility & Capital Allocation
Adjusted net interest expense guidance reduced to ~$2.7 billion (improvement of ~$100 million). Company reiterates commitment to record investment in the business, active BD, and returning capital through a growing dividend.
ABBV Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ABBV Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 29, 2026 | $197.69 | $203.89 | +3.14% |
Feb 04, 2026 | $223.80 | $215.32 | -3.79% |
Oct 31, 2025 | $224.52 | $214.52 | -4.45% |
Jul 31, 2025 | $184.92 | $184.64 | -0.15% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Abbvie (ABBV) report earnings?
Abbvie (ABBV) is schdueled to report earning on Jul 31, 2026, Before Open (Confirmed).
What is Abbvie (ABBV) earnings time?
Abbvie (ABBV) earnings time is at Jul 31, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ABBV EPS forecast?
ABBV EPS forecast for the fiscal quarter 2026 (Q2) is 3.76.
